Literature DB >> 27312006

Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features.

Roeland Lameris1, Renée C G de Bruin1, Paul M P van Bergen En Henegouwen2, Henk M Verheul1, Sonja Zweegman3, Tanja D de Gruijl1, Hans J van der Vliet1.   

Abstract

Ligation of the CD1d antigen-presenting molecule by monoclonal antibodies (mAbs) can trigger important biological functions. For therapeutic purposes camelid-derived variable domain of heavy-chain-only antibodies (VHH) have multiple advantages over mAbs because they are small, stable and have low immunogenicity. Here, we generated 21 human CD1d-specific VHH by immunizing Lama glama and subsequent phage display. Two clones induced maturation of dendritic cells, one clone induced early apoptosis in CD1d-expressing B lymphoblasts and multiple myeloma cells, and another clone blocked recognition of glycolipid-loaded CD1d by CD1d-restricted invariant natural killer T (iNKT) cells. In contrast to reported CD1d-specific mAbs, these CD1d-specific VHH have the unique characteristic that they induce specific and well-defined biological effects. This feature, combined with the above-indicated general advantages of VHH, make the CD1d-specific VHH generated here unique and useful tools to exploit both CD1d ligation as well as disruption of CD1d-iNKT interactions in the treatment of cancer or inflammatory disorders.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  CD1d; cancer; dendritic cell; invariant natural killer T-cell; variable domain of heavy-chain-only antibody

Mesh:

Substances:

Year:  2016        PMID: 27312006      PMCID: PMC4981610          DOI: 10.1111/imm.12635

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  46 in total

Review 1.  NKT cells: what's in a name?

Authors:  Dale I Godfrey; H Robson MacDonald; Mitchell Kronenberg; Mark J Smyth; Luc Van Kaer
Journal:  Nat Rev Immunol       Date:  2004-03       Impact factor: 53.106

2.  Circulating invariant natural killer T-cell numbers predict outcome in head and neck squamous cell carcinoma: updated analysis with 10-year follow-up.

Authors:  Famke L Schneiders; Renée C G de Bruin; Alfons J M van den Eertwegh; Rik J Scheper; C René Leemans; Ruud H Brakenhoff; Johannes A Langendijk; Henk M W Verheul; Tanja D de Gruijl; Johan W Molling; Hans J van der Vliet
Journal:  J Clin Oncol       Date:  2012-01-17       Impact factor: 44.544

3.  Multi-subunit proteins on the surface of filamentous phage: methodologies for displaying antibody (Fab) heavy and light chains.

Authors:  H R Hoogenboom; A D Griffiths; K S Johnson; D J Chiswell; P Hudson; G Winter
Journal:  Nucleic Acids Res       Date:  1991-08-11       Impact factor: 16.971

4.  Exploiting the CD1d-iNKT cell axis for potentiation of DC-based cancer vaccines.

Authors:  Roeland Lameris; Famke L Schneiders; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Methods Mol Biol       Date:  2014

5.  Reduced production of IL-12 and IL-12-dependent IFN-gamma release in patients with allergic asthma.

Authors:  T C van der Pouw Kraan; L C Boeije; E R de Groot; S O Stapel; A Snijders; M L Kapsenberg; J S van der Zee; L A Aarden
Journal:  J Immunol       Date:  1997-06-01       Impact factor: 5.422

Review 6.  Recognition of CD1d-restricted antigens by natural killer T cells.

Authors:  Jamie Rossjohn; Daniel G Pellicci; Onisha Patel; Laurent Gapin; Dale I Godfrey
Journal:  Nat Rev Immunol       Date:  2012-11-16       Impact factor: 53.106

7.  NKT cells mediate pulmonary inflammation and dysfunction in murine sickle cell disease through production of IFN-gamma and CXCR3 chemokines.

Authors:  Kori L Wallace; Melissa A Marshall; Susan I Ramos; Joanne A Lannigan; Joshua J Field; Robert M Strieter; Joel Linden
Journal:  Blood       Date:  2009-05-11       Impact factor: 22.113

8.  By-passing immunization. Human antibodies from V-gene libraries displayed on phage.

Authors:  J D Marks; H R Hoogenboom; T P Bonnert; J McCafferty; A D Griffiths; G Winter
Journal:  J Mol Biol       Date:  1991-12-05       Impact factor: 5.469

9.  Airborne lipid antigens mobilize resident intravascular NKT cells to induce allergic airway inflammation.

Authors:  Seth T Scanlon; Seddon Y Thomas; Caroline M Ferreira; Li Bai; Thomas Krausz; Paul B Savage; Albert Bendelac
Journal:  J Exp Med       Date:  2011-09-19       Impact factor: 14.307

10.  An invariant V alpha 24-J alpha Q/V beta 11 T cell receptor is expressed in all individuals by clonally expanded CD4-8- T cells.

Authors:  P Dellabona; E Padovan; G Casorati; M Brockhaus; A Lanzavecchia
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  5 in total

1.  A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response.

Authors:  Roeland Lameris; Adam Shahine; Daniel G Pellicci; Adam P Uldrich; Stephanie Gras; Jérôme Le Nours; Richard W J Groen; Jana Vree; Scott J J Reddiex; Sergio M Quiñones-Parra; Stewart K Richardson; Amy R Howell; Sonja Zweegman; Dale I Godfrey; Tanja D de Gruijl; Jamie Rossjohn; Hans J van der Vliet
Journal:  Nat Cancer       Date:  2020-09-14

Review 2.  Gamma Delta T-Cell Based Cancer Immunotherapy: Past-Present-Future.

Authors:  José Saura-Esteller; Milon de Jong; Lisa A King; Erik Ensing; Benjamin Winograd; Tanja D de Gruijl; Paul W H I Parren; Hans J van der Vliet
Journal:  Front Immunol       Date:  2022-06-16       Impact factor: 8.786

Review 3.  Theranostics in immuno-oncology using nanobody derivatives.

Authors:  Quentin Lecocq; Yannick De Vlaeminck; Heleen Hanssens; Matthias D'Huyvetter; Geert Raes; Cleo Goyvaerts; Marleen Keyaerts; Nick Devoogdt; Karine Breckpot
Journal:  Theranostics       Date:  2019-10-15       Impact factor: 11.556

4.  Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma.

Authors:  Renée Poels; Esther Drent; Roeland Lameris; Afroditi Katsarou; Maria Themeli; Hans J van der Vliet; Tanja D de Gruijl; Niels W C J van de Donk; Tuna Mutis
Journal:  Int J Mol Sci       Date:  2021-01-22       Impact factor: 5.923

Review 5.  CD1d-Invariant Natural Killer T Cell-Based Cancer Immunotherapy: α-Galactosylceramide and Beyond.

Authors:  Lisa A King; Roeland Lameris; Tanja D de Gruijl; Hans J van der Vliet
Journal:  Front Immunol       Date:  2018-07-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.